TX-OURO
23.4.2024 14:01:58 CEST | Business Wire | Press release
Ouro, a global consumer financial services and technology innovator, and Bnext, a pioneering Spanish fintech, today announced a strategic partnership designating Bnext as Ouro’s strategic issuer in Europe for Ouro’s portfolio of consumer financial brands and products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423392141/en/
Roy Sosa, co-founder and CEO of Ouro (Photo: Business Wire)
Ouro’s innovative payments portfolio includes its flagship Netspend brand that pioneered prepaid debit for underserved U.S. consumers looking for better access to payment products, and X World Wallet, its cashback-earning multicurrency wallet and payments app for international travelers and digital nomads looking for more convenience and value for their money.
“The Bnext team has a proven track record of innovation and understanding of the customer needs of a growing European market for next generation payment products and services,” said Ouro Co-founder and CEO Roy Sosa. “Their entrepreneurial spirit, combined with their technical capabilities and ability to deliver products across European markets make them a perfect partner for Ouro’s ambitious goals,” he added.
Together, Ouro and Bnext will roll out a range of products, programs and partnerships developed and processed by Ouro’s multilingual and multi-currency payments processing platform, and issued by Bnext – including prepaid, debit, digital wallets and other innovative products under development – in Spain and across Europe. The partnership supports Ouro’s strategic focus on innovation, growth, and expansion to global markets.
Bnext and Ouro began their collaboration last year with the launch and distribution of the Correos Prepaid Mastercard product across 2,389 Correos Spanish Post offices throughout Spain. Bnext holds an electronic money issuer license issued by the Bank of Spain and passports to the 27 member states in the EU and Norway. Bnext also holds a Principal Membership from Mastercard.
“Our Correos experience demonstrated Ouro’s sincere commitment to put financial services within reach for everyone, and the speed and impact our joint innovations can make on markets we serve,” said Guillermo Vicandi, co-founder of Bnext. “We’re excited about what the future holds as we work with more partners to deliver even more value to more consumers.”
Launched in March 2023, the Correos Prepaid Mastercard is a globally accepted, prepaid debit account customers can access with a card and mobile app to manage their finances, direct deposit salaries and government benefits, spend in stores and online, transfer funds, and open a Spanish bank account. They can also withdraw cash from ATMs and from Correos’ network of offices throughout Spain.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro's financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit www.ouro.com.
About Bnext
Bnext is an electronic money entity registered with the Bank of Spain. Within two years of its founding in 2017, Bnext reached a record 500,000 users. Bnext’s growing range of products and services includes financial services, loyalty and refund programs, as well as third-party financial services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423392141/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom